JP2005522527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522527A5 JP2005522527A5 JP2004545736A JP2004545736A JP2005522527A5 JP 2005522527 A5 JP2005522527 A5 JP 2005522527A5 JP 2004545736 A JP2004545736 A JP 2004545736A JP 2004545736 A JP2004545736 A JP 2004545736A JP 2005522527 A5 JP2005522527 A5 JP 2005522527A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- animals
- log
- days
- cell kill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 9
- 238000011282 treatment Methods 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27562701P | 2001-03-15 | 2001-03-15 | |
| US60/275,627 | 2001-03-15 | ||
| PCT/EP2002/006758 WO2004037258A1 (en) | 2001-03-15 | 2002-03-15 | A combination comprising combretastatin and anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005522527A JP2005522527A (ja) | 2005-07-28 |
| JP2005522527A5 true JP2005522527A5 (https=) | 2012-03-29 |
| JP4991107B2 JP4991107B2 (ja) | 2012-08-01 |
Family
ID=23053164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004545736A Expired - Fee Related JP4991107B2 (ja) | 2001-03-15 | 2002-03-15 | コンブレタスタチンおよび抗癌剤からなる組成物 |
Country Status (37)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999051246A1 (en) | 1998-04-03 | 1999-10-14 | Ajinomoto Co., Inc. | Antitumor agents |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| GB0410817D0 (en) * | 2004-05-14 | 2004-06-16 | Angiogene Pharm Ltd | Vascular damaging therapy |
| CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| CN1319978C (zh) * | 2005-04-06 | 2007-06-06 | 西南合成制药股份有限公司 | 康布瑞汀化合物的制备方法 |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| US20080104512A1 (en) * | 2006-10-31 | 2008-05-01 | Motorola, Inc. | Method and apparatus for providing realtime feedback in a voice dialog system |
| WO2009067706A1 (en) * | 2007-11-21 | 2009-05-28 | Oxigene, Inc. | Method for treating hematopoietic neoplasms |
| WO2009103076A1 (en) * | 2008-02-15 | 2009-08-20 | Oxigene, Inc. | Methods and compositions for enhancing the efficacy of rtk inhibitors |
| FR2939665B1 (fr) * | 2008-12-12 | 2011-10-07 | Sanofi Aventis | Combinaison antitumorale associant l'ave8062a et le docetaxel |
| FR2945210B1 (fr) | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
| BR112012031917A2 (pt) | 2010-06-18 | 2017-11-28 | Sanofi Sa | combinação antitumoral compreendendo ombrabulina, um derivado de taxano e um derivado de platina |
| EP2481404A1 (en) | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP2397135A1 (en) | 2010-06-18 | 2011-12-21 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
| FR2968557A1 (fr) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
| FR2978662A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| US9980953B2 (en) * | 2016-09-26 | 2018-05-29 | Chong Kun Dang Pharmaceutical Corp. | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| WO1999051246A1 (en) * | 1998-04-03 | 1999-10-14 | Ajinomoto Co., Inc. | Antitumor agents |
| US6242770B1 (en) * | 1998-08-31 | 2001-06-05 | Gary Bela Bronner | Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same |
| GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| DE60031268T2 (de) * | 1999-04-14 | 2007-05-24 | Dana-Farber Cancer Institute, Inc., Boston | Verfahren und zusammansetzung zur behandlung von krebs |
| US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| AU1602902A (en) * | 2000-10-27 | 2002-05-06 | Aventis Pharma Sa | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| AU2002246827B2 (en) * | 2000-12-22 | 2008-02-21 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
| US6466448B1 (en) * | 2001-06-11 | 2002-10-15 | Network Appliance, Inc. | Riser board retaining and air ducting structure for printed circuit boards |
-
2002
- 2002-03-08 US US10/092,508 patent/US20020183266A1/en not_active Abandoned
- 2002-03-14 UY UY27208A patent/UY27208A1/es not_active Application Discontinuation
- 2002-03-14 AR ARP020100914A patent/AR032989A1/es unknown
- 2002-03-15 CA CA2673449A patent/CA2673449C/en not_active Expired - Fee Related
- 2002-03-15 ME MEP-2008-162A patent/ME00056B/me unknown
- 2002-03-15 HR HR20030734A patent/HRPK20030734B3/xx not_active IP Right Cessation
- 2002-03-15 PE PE2002000204A patent/PE20020909A1/es not_active Application Discontinuation
- 2002-03-15 AU AU2002304574A patent/AU2002304574B2/en not_active Ceased
- 2002-03-15 HU HU0600233A patent/HU228510B1/hu not_active IP Right Cessation
- 2002-03-15 DK DK02732758T patent/DK1439839T3/da active
- 2002-03-15 TW TW091104922A patent/TWI306028B/zh not_active IP Right Cessation
- 2002-03-15 PL PL374406A patent/PL205728B1/pl not_active IP Right Cessation
- 2002-03-15 WO PCT/EP2002/003322 patent/WO2002074229A2/en not_active Ceased
- 2002-03-15 SK SK1155-2003A patent/SK287908B6/sk not_active IP Right Cessation
- 2002-03-15 UA UA2003109292A patent/UA75127C2/uk unknown
- 2002-03-15 CN CN2006101388753A patent/CN1935134B/zh not_active Expired - Fee Related
- 2002-03-15 AT AT02732758T patent/ATE433750T1/de active
- 2002-03-15 SI SI200230915T patent/SI1439839T1/sl unknown
- 2002-03-15 EA EA200301015A patent/EA006316B1/ru not_active IP Right Cessation
- 2002-03-15 JP JP2004545736A patent/JP4991107B2/ja not_active Expired - Fee Related
- 2002-03-15 US US10/097,926 patent/US6933320B2/en not_active Expired - Fee Related
- 2002-03-15 KR KR1020037012033A patent/KR100849610B1/ko not_active Expired - Fee Related
- 2002-03-15 BR BR0208017-6A patent/BR0208017A/pt not_active IP Right Cessation
- 2002-03-15 WO PCT/EP2002/006758 patent/WO2004037258A1/en not_active Ceased
- 2002-03-15 RS YUP-713/03A patent/RS50682B/sr unknown
- 2002-03-15 NO NO20034022A patent/NO332661B1/no not_active IP Right Cessation
- 2002-03-15 ME MEP-162/08A patent/MEP16208A/xx unknown
- 2002-03-15 CZ CZ20032476A patent/CZ302451B6/cs not_active IP Right Cessation
- 2002-03-15 MX MXPA03007552A patent/MXPA03007552A/es active IP Right Grant
- 2002-03-15 ES ES02732758T patent/ES2327617T3/es not_active Expired - Lifetime
- 2002-03-15 IL IL15789102A patent/IL157891A0/xx unknown
- 2002-03-15 NZ NZ527526A patent/NZ527526A/en not_active IP Right Cessation
- 2002-03-15 CN CNB028065832A patent/CN1290504C/zh not_active Expired - Fee Related
- 2002-03-15 CA CA002470484A patent/CA2470484C/en not_active Expired - Fee Related
- 2002-03-15 EP EP02732758A patent/EP1439839B8/en not_active Expired - Lifetime
- 2002-03-15 DE DE60232673T patent/DE60232673D1/de not_active Expired - Lifetime
- 2002-03-15 PT PT02732758T patent/PT1439839E/pt unknown
-
2003
- 2003-07-08 TN TNPCT/EP2002/003322A patent/TNSN03060A1/en unknown
- 2003-08-29 ZA ZA2003/06789A patent/ZA200306789B/en unknown
- 2003-09-09 MA MA27301A patent/MA27000A1/fr unknown
- 2003-09-11 IL IL157891A patent/IL157891A/en not_active IP Right Cessation
- 2003-09-12 EC EC2003004766A patent/ECSP034766A/es unknown
-
2004
- 2004-11-23 US US10/995,998 patent/US20050075295A1/en not_active Abandoned
-
2007
- 2007-02-21 US US11/677,178 patent/US20070149476A1/en not_active Abandoned
-
2009
- 2009-09-16 CY CY20091100954T patent/CY1109364T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522527A5 (https=) | ||
| KR100334051B1 (ko) | 탁산유도체를함유하는항종양조성물 | |
| Einhorn | Testicular cancer: an oncological success story. | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| Capizzi | Improvement in the therapeutic index of methotrexate (NSC-740) by L-asparaginase (NSC-109229) | |
| WO2010012777A1 (en) | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT | |
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| RU2000132310A (ru) | Применение продуктов на основе магния для лечения или профилактики опухолевых и аутоиммунных заболеваний | |
| AU2010244254A1 (en) | Antitumor combination including AVE8062 and sorafenib | |
| JP2002523437A5 (https=) | ||
| Venditti et al. | Chemotherapy of advanced mouse leukemia L1210: comparison of methotrexate alone and in sequential therapy | |
| JP2005502690A5 (https=) | ||
| Choy et al. | Paclitaxel, Carboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer | |
| Lang et al. | Therapeutic effects of roxithromycin and azithromycin in experimental murine brucellosis | |
| Moertel et al. | Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer | |
| Smith Jr et al. | The effects of cyclophosphamide, ketoconazole, aclacinomycin‐A, methotrexate, and scheduled methotrexate‐5‐fluorouracil combination chemotherapy on the transplantable R‐3327 prostatic adenocarcinoma in the F1 hybrid male rat | |
| Satta et al. | Beyond 5-fluorouracil monochemotherapy in colorectal cancer–it is time | |
| KR20210039413A (ko) | 암의 치료를 위한 병용 요법 | |
| Atef et al. | Effect of pyridoxine on the distribution of chloramphenicol and its residues in the chicken | |
| CN101185628A (zh) | 一种治疗实体肿瘤的依立替康缓释植入剂 | |
| Bleehen et al. | The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study | |
| Rossetti | Single-shot vs conventional therapy with amikacin for treatment of uncomplicated urinary tract infections: a multicenter study | |
| Maslov et al. | Effect of peroxidase in complex with basic antileprosy drugs on liver, blood, and functional activity of phagocytes in mice with experimental leprosy | |
| EA | K&hmi M, Fijita H, Haneda H, Akita H, Kuzumaki N, MiyPmoto H et Pl. Laboratory ojhfolecular Genetics, Cancer Insritute, H&aid0 |